Survival and desferrioxamine in thalassaemia major.

Desferrioxamine in thalassaemia.

Survival in thalassaemia major patients.

BACKGROUND The present study evaluated the prognostic significance of Doppler-demonstrated left ventricular (LV) restrictive filling pattern (RFP) in patients with thalassaemia major (TM), which carries an adverse cardiovascular prognosis. METHODS AND RESULTS The study group comprised 45 asymptomatic transfusion-dependent patients with TM and normal LV systolic function. All patients were che...

Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.

Liver biopsies were performed on 51 regularly transfused patients with beta thalassaemia, age range 5-36 (mean 18.6) years, who had received regular subcutaneous desferrioxamine (DFX) treatment for periods between one and eight years (40 for eight years). The biopsy specimens were examined by light microscopy and immunofluorescence for hepatitis B virus surface and core antigens (HBsAg and HBcA...

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.

About 50% of UK patients with beta-thalassaemia major die before the age of 35 years, mainly because conventional iron-chelation therapy is too burdensome for full adherence. Patients require an individually-tailored treatment plan incorporating new, more tolerable approaches.

Urinary iron excretion in thalassaemia after desferrioxamine administration.

oxamine administration. Urinary iron excretion induced with desferrioxamine (DFA) was estimated in 26 children with thalassaemia major. Four separate 24-hour urine collections were made-during a baseline period, after intramuscular injection of DFA 1 g, during blood transfusion with DFA 0 5 g/unit transfused blood, and during the post-transfusion period. Urinary iron, plasma iron, and total iro...